Federal Upper Limit Dimitry Gotlinsky Western University.

Slides:



Advertisements
Similar presentations
Issues and Compliance Strategies Related to Government Pricing Joseph W. Metro.
Advertisements

Beyond Average Wholesale Price….
Understanding Mail Order Community pharmacists provide a valuable service desired by patients. Very rarely are mail order and community pharmacies allowed.
Average Wholesale Price (AWP) Sapna N. Patel UCSF Pharm. D. Candidate 2008 Preceptor Dr. Craig S. Stern March 7, 2008.
Overview of Drug Purchasing & Pricing
Pharmacy Benefit Managers (PBMs)
Mylan Laboratories Inc. (MYL) Solomon Lee, Analyst Graduation Date: April 2008.
Pharmacy Program Initiatives Threshold, Mandatory Generic, Maximum Allowable Cost (MAC) Javier Menendez, RPh Pharmacy Manager Department of Medical Assistance.
2.05d Determine Discounts and Allowances that can be used to adjust base prices.
South Carolina Hospital Association HITECH Stimulus Calculator These worksheets have been forwarded to South Carolina hospital CFOs. They provide hospital-
Generic Substitution Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
State Maximum Allowable Cost (SMAC) Implementation Updates and Changes to DC Point-of-Sale Pricing Structure.
Authorized Generics: Good For Everyone (Even Generics) Jerome A. Swindell Senior Counsel.
Are Drug Pricing Formulas Full Employment Acts For State Attorney Generals? Gerard Anderson PhD Professor Johns Hopkins University.
THE PREVALENCE AND PREDICTORS OF LOW-COST GENERIC PROGRAM USE IN A NATIONALLY REPRESENTATIVE ADULT POPULATION: IMPLICATIONS FOR PATIENTS, RESEARCH, AND.
1 State Perspectives on Medicare Part D: Lessons from Pharmacy Plus Programs Cindy Parks Thomas Donald Shepard Christine E. Bishop Daniel M. Gilden Brandeis.
Copay Structure Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
Pharmacology Chapter 17. Pharmacology  Definition  The effect of drugs on the body and the effect of the body on drugs.
Medicare Modernization Act: Impact of State Implementation Decisions Haiden Huskamp AcademyHealth June 28, 2005.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
Responding to Enforcement Initiatives: Designing the Successor(s) to the Medicaid Rebate Program The Fourth Annual Pharmaceutical Regulatory and Compliance.
Avalere Health LLC | The intersection of business strategy and public policy Medicaid Pharmacy Reimbursement Overview June 13, 2007 Jennifer Kowalski Avalere.
Focus on the Drug Payment Methods Landscape Academy of Managed Care Pharmacy April 17, 2009.
Mail Order Pharmacy What You Don’t Know Will Hurt You!
Slide 1 Drug Pricing Considerations Medicare Prescription Drug, Improvement, and Modernization Act of 2003 ___________ Copyright 2005 Arnold & Porter July.
PwC Pharmaceutical Drug Pricing and Reporting Issues A Brief Overview of Government Drug Price Reporting Requirements July 28, 2005 National Parma Audioconference.
© Hogan & Hartson LLP. All rights reserved. Alice Valder Curran, Partner Tuesday, October 17, 2006 Private Prices, Public Markets: The Evolution of Price.
Ian D. Spatz Merck & Co., Inc. January 14, 2004 Ian D. Spatz Merck & Co., Inc. January 14, 2004 Overview of the New Medicare Prescription Drug Law.
New Analysis of DRE Savings for States & Federal Government September 22, 2008.
1 Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Title III – Combating Waste, Fraud, and Abuse Janet Rehnquist, Esq. Venable LLP.
Dan Lindenmeyer, RPh Pharmacy Mgr. - Dillons.  6 main categories ◦ Hypertension ◦ Antidepressants ◦ Pain meds ◦ Cholesterol Reducers ◦ Antibiotics ◦
Avalere Health LLC | The intersection of business strategy and public policy Overview of Coverage of Drugs Under the Medicaid Medical Benefit June 4, 2008.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
THE SECOND ANNUAL FDA REGULATORY AND COMPLIANCE SYMPOSIUM THOMAS M. GREENE Greene & Hoffman August 25, 2006 LESSONS FROM WHISTLE-BLOWER CASES.
Zokufa HZ, Pillay T Pharmaceutical Policy and Planning National Department of Health- South Africa.
Practical Issues for PBMs in Medicare Part D Bob Atlas NASI Medicare Modernization Conference January 27, 2005.
Pricing Under ASP Manufacturers submit quarterly ASP data by 11- digit National Drug Code (NDC) For multiple source drugs, the payment allowance limit.
Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies.
MEDICARE PART D July MEDICARE PART D: OVERVIEW Part D provides prescription drug coverage for Medicare beneficiaries. Prescription drug plans compete.
Managed Care Pharmacy Financials January 15, 2015.
Drug Formulary Development & Management
How Pharmacy Benefit Managers Work April 28, 2016 Producer: Alexander Perry Director: Afzal Bari.
Pharmacy Benefit Management (PBM) 101
Drug Payment Methodologies
340B PROGRAM AND BEST PRICE LAW HIGPA 2003 National Pharmacy Forum February 4, 2003 Presentation By Ted Slafsky Director Public Hospital Pharmacy Coalition.
Reimbursement Trends & Observations Presented by: John Aforismo B.Sc. Pharm., R.Ph Chairman & Founder RJ Health Systems International, LLC AMCP 21 st Annual.
Connecticut Pharmaceutical Forum: Access, Affordability, and Better Health Tara C. F. Ryan May 17, 2016.
Drug Payment Methodologies Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2016.
Wise Pharmaceuticals Ltd. Headquarter at Oxford House, Oxford Street, Manchester M1 5EA U.K is a Limited company.
Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.
MEDICATION USE IN RURAL AMERICA ASSOCIATION UPDATES National Community Pharmacists Association Tina Schlecht, PharmD, MBA Director, Pharmacy Affairs.
Changes to AMP & Best Price: Impact on 340B Pricing February 1, 2008 Long Beach, California 4 th Annual 340B Coalition Winter Conference University of.
Pharmaceuticals Chapter 11 Part 1.
Hemophilia Alliance Fall Meeting 2017
An Increasing Demand for Prescription Drugs Drives Profitability
Pharmaceutical Pricing and Contracting: An Overview March 2006
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Title III – Combating Waste, Fraud, and Abuse Janet Rehnquist, Esq. Venable.
John M. Coster, Ph.D., R.Ph. Vice President, Policy and Programs
Pharmacy: Pharmacy Landscape and Uncovering the Optical Illusions
Medicare Rx Legislation: Implications for PBMs
Pharmacy Reimbursement and Manufacturer Rebate Formulas (Part 3)
Pharmacy – Fully Insured versus Self Funding
Medicare Reform: Implications for Pharmaceutical Manufacturers
Drug Formulary Development & Management
Presentation transcript:

Federal Upper Limit Dimitry Gotlinsky Western University

Rx Pricing It is extremely difficult to understand U.S. pharmaceutical pricing Not everyone pays the same price Prices for different payers are often a secret The only official price released by pharmaceutical company is called WAC

WAC (whole sale acquisition cost)- The price paid by a wholesaler for drugs purchased from the wholesaler's supplier AWP (avg, wholesale price) –an average of list prices quoted by wholesalers to pharmacies - AMP (avg. manufacturer price)-an average price paid to manufacturer by wholesalers for drugs distributed to retail pharmacies -AMP is used in calculating Medicaid Rebates

What is FUL? In 1987 CMS (centers for Medicare & Medicaid Services) established a Federal Upper Limit FUL was established to limit the amount that Medicaid could reimburse for multiple-source drugs Multiple source drugs-is the same as generic, but multiple manufacturers make the same medication

How does a drug get picked to be on FUL? 2 criteria's must be met 1)there must be 3 or more versions of the drug rated therapeutically equivalent by the FDA (A rated) 2) and the drug has at least three suppliers listed in current editions of national compendia

Problem with FUL FUL is updated only twice a year Not all categories of drugs are covered under FUL

Reasons why generics may not have FUL 1. Very old generic 2. Recently marketed generics for single source drugs whose patents just expired 3. generic may have a 6 months period of exclusivity granted by the FDA

What does it mean? Drug price competition benefits Medicaid reimbursements Example In August 2001, a generic form of Prozac called Fluoxetine became available Before the 1 st generic was available Medicaid was reimbursing $2.86 per capsule Once the 1 st generic became available (it had 6 months exclusivity period) Medicaid was reimbursing $2.46/capsule After the 6 months exclusivity period, reimbursement was $.70/cap This sets an incentive for pharmacies to purchase generics at lower than FUL price.

Drug classes covered under FUL Narcotic analgesics (tylenol w/codeine) Anti-virals (acyclovir) Anti-gout (allopurinol) Benzodiazepines (alprazolam) B-blokers (atenolol) Bronchodialators (albuterol) Diuretics (bumetanide) ACE inhibitors (captopril) Anti-histamines (chlorpheniramine) Cephalosporins (Keflex) Antifungals (ketokonazole)

Continued H-2-antagonists (cimetidine) TCA (clomipramine) NSAIDs (diclofenac) Topical steroids (desonide) Ca channel blockeers (diltiazem) SSRI (fluoxetine) Muscle relaxants (carisoprodol) Alpha adrenergic blockers (doxazosin) Statin (lovastatin) Sufonylureal (glyburide) Typical antipsychotic (haldol)

Drugs not included in FUL These drugs meet the FUL criteria but are not included in the FUL Clozapine (anti-psychotic) Morphine Sulfate (opioid) Phentermine HCl (anorectic) Sotalol HCl (anti-arrhythmic) Bupropion (anti-depressant) Clotrimazole cream (anti-fungal) Dipyridamole (platelet aggregation inhibitor)

. ● Since FUL does not cover all the drugs, MAC (maximum alloawble cost) was established ● PBM and TPA use MAC lists to cover all generic medications ●Unlike FUL, MAC is updated monthly

Recommendation FULs were created to help Medicaid save money by taking advantage of lower prices for multiple-source drugs available There are more drugs that fit the criteria to be added to FUL By including more drugs to FULs that meet the requirement, can save millions of dollars to State Medicaid Also, updating FUL at least once a month would encourage greater use of cost-effective generic drugs

THE END